Understanding the relationship between norovirus diversity and immunity

References

• Thorne LG, Goodfellow IG. Norovirus gene expression and replication. J Gen Virol. 2014;95(Pt 2):278–13. doi:10.1099/vir.0.059634-0.
   Google Scholar
• Prasad BV, Hardy ME, Dokland T, Bella J, Rossmann MG, Estes MK. X-ray crystallographic structure of the Norwalk virus capsid. Science. 1999;286(5438):287–290. doi:10.1126/science.286.5438.287.
   Google Scholar
• Jiang X, Wang M, Graham DY, Estes MK. Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J Virol. 1992;66(11):6527–6532. doi:10.1128/JVI.66.11.6527-6532.1992.
   Google Scholar
• Devant JM, Hofhaus G, Bhella D, Hansman GS. Heterologous expression of human norovirus GII.4 VP1 leads to assembly of T=4 virus-like particles. Antiviral Res. 2019;168:175–182. doi:10.1016/j.antiviral.2019.05.010.
   Google Scholar
• Jung J, Grant T, Thomas DR, Diehnelt CW, Grigorieff N, Joshua-Tor L. High-resolution cryo-EM structures of outbreak strain human norovirus shells reveal size variations. Proc Natl Acad Sci U S A. 2019;116(26):12828–12832. doi:10.1073/pnas.1903562116.
   Google Scholar
• Ajami NJ, Barry MA, Carrillo B, Muhaxhiri Z, Neill FH, Prasad BV, Opekun AR, Gilger MA, Graham DY, Atmar RL, et al. Antibody responses to norovirus genogroup GI.1 and GII.4 proteases in volunteers administered Norwalk virus. Clin Vaccine Immunol. 2012;19(12):1980–1983. doi:10.1128/CVI.00411-12.
   Google Scholar
• Atmar RL, Ramani S, Estes MK. Human noroviruses: recent advances in a 50-year history. Curr Opin Infect Dis. 2018;31(5):422–432. doi:10.1097/QCO.0000000000000476.
   Google Scholar
• Parra GI, Azure J, Fischer R, Bok K, Sandoval-Jaime C, Sosnovtsev SV, Sander P, Green KY, Jhaveri R. Identification of a broadly cross-reactive epitope in the inner shell of the norovirus capsid. PLoS One. 2013;8(6):e67592. doi:10.1371/journal.pone.0067592.
   Google Scholar
• Parra GI, Sosnovtsev SV, Abente EJ, Sandoval-Jaime C, Bok K, Dolan MA, Green KY. Mapping and modeling of a strain-specific epitope in the Norwalk virus capsid inner shell. Virology. 2016;492:232–241. doi:10.1016/j.virol.2016.02.019.
   Google Scholar
• Alvarado G, Ettayebi K, Atmar RL, Bombardi RG, Kose N, Estes MK, Crowe JE Jr. Human Monoclonal Antibodies That Neutralize Pandemic GII.4 Noroviruses. Gastroenterology. 2018;155(6):1898–1907. doi:10.1053/j.gastro.2018.08.039.
   Google Scholar
• Ford-Siltz LA, Wales S, Tohma K, Gao Y, Parra GI. Genotype-specific neutralization of norovirus is mediated by antibodies against the protruding domain of the major capsid protein. J Infect Dis. 2020. doi:10.1093/infdis/jiaa116.
   Google Scholar
• Lindesmith LC, McDaniel JR, Changela A, Verardi R, Kerr SA, Costantini V, Brewer-Jensen PD, Mallory ML, Voss WN, Boutz DR, et al. Sera antibody repertoire analyses reveal mechanisms of broad and pandemic strain neutralizing responses after human norovirus vaccination. Immunity. 2019;50(6):1530–1541 e8. doi:10.1016/j.immuni.2019.05.007.
   Google Scholar
• Koromyslova AD, Morozov VA, Hefele L, Hansman GS. Human norovirus neutralized by a monoclonal antibody targeting the histo-blood group antigen pocket. J Virol. 2019;93(5):e02174-18.
   Google Scholar
• Bok K, Parra GI, Mitra T, Abente E, Shaver CK, Boon D, Engle R, Yu C, Kapikian AZ, Sosnovtsev SV, et al. Chimpanzees as an animal model for human norovirus infection and vaccine development. Proc Natl Acad Sci U S A. 2011;108(1):325–330. doi:10.1073/pnas.1014577107.
   Google Scholar
• Hansman GS, Taylor DW, McLellan JS, Smith TJ, Georgiev I, Tame JR, Park SY, Yamazaki M, Gondaira F, Miki M, et al. Structural basis for broad detection of genogroup II noroviruses by a monoclonal antibody that binds to a site occluded in the viral particle. J Virol. 2012;86(7):3635–3646. doi:10.1128/JVI.06868-11.
   Google Scholar
• Chhabra P, De Graaf M, Parra GI, Chan MC, Green K, Martella V, Wang Q, White PA, Katayama K, Vennema H, et al. Updated classification of norovirus genogroups and genotypes. J Gen Virol. 2019;100(10):1393–1406. doi:10.1099/jgv.0.001318.
   Google Scholar
• Parra GI, Squires RB, Karangwa CK, Johnson JA, Lepore CJ, Sosnovtsev SV, Green KY, Sestak K. Static and evolving norovirus genotypes: implications for epidemiology and immunity. PLoS Pathog. 2017;13(1):e1006136. doi:10.1371/journal.ppat.1006136.
   Google Scholar
• Parra GI. Emergence of norovirus strains: a tale of two genes. Virus Evol. 2019;5(2):vez048. doi:10.1093/ve/vez048.
   Google Scholar
• Siebenga JJ, Vennema H, Zheng DP, Vinje J, Lee BE, Pang XL, Ho EC, Lim W, Choudekar A, Broor S, et al. Norovirus illness is a global problem: emergence and spread of norovirus GII.4 variants, 2001-2007. J Infect Dis. 2009;200(5):802–812. doi:10.1086/605127.
   Google Scholar
• Lanata CF, Fischer-Walker CL, Olascoaga AC, Torres CX, Aryee MJ, Black RE. Child health epidemiology reference group of the World Health, O., Unicef, Global causes of diarrheal disease mortality in children <5 years of age: a systematic review. PLoS One. 2013;8:e72788.
   Google Scholar
• Lopman BA, Steele D, Kirkwood CD, Parashar UD. The vast and varied global burden of norovirus: prospects for prevention and control. PLoS Med. 2016;13(4):e1001999. doi:10.1371/journal.pmed.1001999.
   Google Scholar
• Atmar RL, Opekun AR, Gilger MA, Estes MK, Crawford SE, Neill FH, Graham DY. Norwalk virus shedding after experimental human infection. Emerg Infect Dis. 2008;14(10):1553–1557. doi:10.3201/eid1410.080117.
   Google Scholar
• Bok K, Green KY. Norovirus gastroenteritis in immunocompromised patients. N Engl J Med. 2012;367(22):2126–2132. doi:10.1056/NEJMra1207742.
   Google Scholar
• Bartsch SM, Lopman BA, Ozawa S, Hall AJ, Lee BY, Olson DR. Global economic burden of norovirus gastroenteritis. PLoS One. 2016;11(4):e0151219. doi:10.1371/journal.pone.0151219.
   Google Scholar
• Rockx BH, Vennema H, Hoebe CJ, Duizer E, Koopmans MP. Association of histo-blood group antigens and susceptibility to norovirus infections. J Infect Dis. 2005;191(5):749–754. doi:10.1086/427779.
   Google Scholar
• Le Pendu J, Ruvoen-Clouet N. Fondness for sugars of enteric viruses confronts them with human glycans genetic diversity. Hum Genet. 2019;139(6–7):903–910. doi:10.1007/s00439-019-02090-w.
   Google Scholar
• Haga K, Ettayebi K, Tenge VR, Karandikar UC, Lewis MA, Lin SC, Neill FH, Ayyar BV, Zeng XL, Larson G, et al. Genetic manipulation of human intestinal enteroids demonstrates the necessity of a functional fucosyltransferase 2 gene for secretor-dependent human norovirus infection. mBio. 2020;11(2). doi:10.1128/mBio.00251-20.
   Google Scholar
• Ravn V, Dabelsteen E. Tissue distribution of histo-blood group antigens. APMIS. 2000;108(1):1–28. doi:10.1034/j.1600-0463.2000.d01-1.x.
   Google Scholar
• Marionneau S, Cailleau-Thomas A, Rocher J, Le Moullac-Vaidye B, Ruvoen N, Clement M, Le Pendu J. ABH and Lewis histo-blood group antigens, a model for the meaning of oligosaccharide diversity in the face of a changing world. Biochimie. 2001;83(7):565–573. doi:10.1016/S0300-9084(01)01321-9.
   Google Scholar
• Thorven M, Grahn A, Hedlund KO, Johansson H, Wahlfrid C, Larson G, Svensson L. A homozygous nonsense mutation (428G–>A) in the human secretor (FUT2) gene provides resistance to symptomatic norovirus (GGII) infections. J Virol. 2005;79(24):15351–15355. doi:10.1128/JVI.79.24.15351-15355.2005.
   Google Scholar
• Larsson MM, Rydell GE, Grahn A, Rodriguez-Diaz J, Akerlind B, Hutson AM, Estes MK, Larson G, Svensson L. Antibody prevalence and titer to norovirus (genogroup II) correlate with secretor (FUT2) but not with ABO phenotype or Lewis (FUT3) genotype. J Infect Dis. 2006;194(10):1422–1427. doi:10.1086/508430.
   Google Scholar
• Frenck R, Bernstein DI, Xia M, Huang P, Zhong W, Parker S, Dickey M, McNeal M, Jiang X. Predicting susceptibility to norovirus GII.4 by use of a challenge model involving humans. J Infect Dis. 2012;206(9):1386–1393. doi:10.1093/infdis/jis514.
   Google Scholar
• Lindesmith L, Moe C, Marionneau S, Ruvoen N, Jiang X, Lindblad L, Stewart P, LePendu J, Baric R. Human susceptibility and resistance to Norwalk virus infection. Nat Med. 2003;9(5):548–553. doi:10.1038/nm860.
   Google Scholar
• Ettayebi K, Crawford SE, Murakami K, Broughman JR, Karandikar U, Tenge VR, Neill FH, Blutt SE, Zeng XL, Qu L, et al. Replication of human noroviruses in stem cell-derived human enteroids. Science. 2016;353(6306):1387–1393. doi:10.1126/science.aaf5211.
   Google Scholar
• Atmar RL, Bernstein DI, Lyon GM, Treanor JJ, Al-Ibrahim MS, Graham DY, Vinje J, Jiang X, Gregoricus N, Frenck RW, et al. Serological correlates of protection against a gii.4 norovirus. Clin Vaccine Immunol. 2015;22(8):923–929. doi:10.1128/CVI.00196-15.
   Google Scholar
• Reeck A, Kavanagh O, Estes MK, Opekun AR, Gilger MA, Graham DY, Atmar RL. Serological correlate of protection against norovirus-induced gastroenteritis. J Infect Dis. 2010;202(8):1212–1218. doi:10.1086/656364.
   Google Scholar
• Atmar RL, Ettayebi K, Ayyar BV, Neill FH, Braun RP, Ramani S, Estes MK. Comparison of Microneutralization and Histo-Blood Group Antigen-Blocking Assays for Functional Norovirus Antibody Detection. J Infect Dis. 2020;221(5):739–743. doi:10.1093/infdis/jiz526.
   Google Scholar
• Kendra JA, Tohma K, Ford-Siltz LA, Lepore CJ, Parra GI. Antigenic cartography reveals complexities of the genetic determinants that lead to antigenic differences among pandemic GII.4 noroviruses. Proc Natl Acad Sci U S A. 2021;118(11).e2015874118.
   Google Scholar
• Cheetham S, Souza M, Meulia T, Grimes S, Han MG, Saif LJ. Pathogenesis of a genogroup II human norovirus in gnotobiotic pigs. J Virol. 2006;80(21):10372–10381. doi:10.1128/JVI.00809-06.
   Google Scholar
• Han MG, Cheetham S, Azevedo M, Thomas C, Saif LJ. Immune responses to bovine norovirus-like particles with various adjuvants and analysis of protection in gnotobiotic calves. Vaccine. 2006;24(3):317–326. doi:10.1016/j.vaccine.2005.07.071.
   Google Scholar
• Taube S, Kolawole AO, Hohne M, Wilkinson JE, Handley SA, Perry JW, Thackray LB, Akkina R, Wobus CE, Dermody TS. A mouse model for human norovirus. mBio. 2013;4(4). doi:10.1128/mBio.00450-13.
   Google Scholar
• Karangwa CK, Parra GI, Bok K, Johnson JA, Levenson EA, Green KY. Sequential Gastroenteritis Outbreaks in a Single Year Caused by Norovirus Genotypes GII.2 and GII.6 in an Institutional Setting. Open Forum Infect Dis. 2017;4(4):ofx236. doi:10.1093/ofid/ofx236.
   Google Scholar
• Parrino TA, Schreiber DS, Trier JS, Kapikian AZ, Blacklow NR. Clinical immunity in acute gastroenteritis caused by Norwalk agent. N Engl J Med. 1977;297(2):86–89. doi:10.1056/NEJM197707142970204.
   Google Scholar
• Wyatt RG, Dolin R, Blacklow NR, DuPont HL, Buscho RF, Thornhill TS, Kapikian AZ, Chanock RM. Comparison of three agents of acute infectious nonbacterial gastroenteritis by cross-challenge in volunteers. J Infect Dis. 1974;129(6):709–714. doi:10.1093/infdis/129.6.709.
   Google Scholar
• Ramani S, Neill FH, Opekun AR, Gilger MA, Graham DY, Estes MK, Atmar RL. Mucosal and cellular immune responses to Norwalk Virus. J Infect Dis. 2015;212(3):397–405. doi:10.1093/infdis/jiv053.
   Google Scholar
• Atmar RL, Bernstein DI, Harro CD, Al-Ibrahim MS, Chen WH, Ferreira J, Estes MK, Graham DY, Opekun AR, Richardson C, et al. Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med. 2011;365(23):2178–2187. doi:10.1056/NEJMoa1101245.
   Google Scholar
• Cortes-Penfield NW, Ramani S, Estes MK, Atmar RL. Prospects and challenges in the development of a Norovirus vaccine. Clin Ther. 2017;39(8):1537–1549. doi:10.1016/j.clinthera.2017.07.002.
   Google Scholar
• Costantini VP, Cooper EM, Hardaker HL, Lee LE, DeBess EE, Cieslak PR, Hall AJ, Vinje J. Humoral and mucosal immune responses to human norovirus in the elderly. J Infect Dis. 2020;221(11):1864–1874. doi:10.1093/infdis/jiaa021.
   Google Scholar
• Sapparapu G, Czako R, Alvarado G, Shanker S, Prasad BV, Atmar RL, Estes MK, Crowe JE Jr. Frequent use of the IgA Isotype in human b cells encoding potent norovirus-specific monoclonal antibodies that block HBGA binding. PLoS Pathog. 2016;12(6):e1005719. doi:10.1371/journal.ppat.1005719.
   Google Scholar
• Onodera T, Hashi K, Shukla RK, Miki M, Takai-Todaka R, Fujimoto A, Kuraoka M, Miyoshi T, Kobayashi K, Hasegawa H, et al. Immune-focusing properties of virus-like particles improve protective IgA responses. J Immunol. 2019;203(12):3282–3292. doi:10.4049/jimmunol.1900481.
   Google Scholar
• Parra GI, Green KY. Sequential gastroenteritis episodes caused by 2 norovirus genotypes. Emerg Infect Dis. 2014;20(6):1016–1018. doi:10.3201/eid2006.131627.
   Google Scholar
• Hansman GS, Natori K, Shirato-Horikoshi H, Ogawa S, Oka T, Katayama K, Tanaka T, Miyoshi T, Sakae K, Kobayashi S, et al. Genetic and antigenic diversity among noroviruses. J Gen Virol. 2006;87(Pt 4):909–919. doi:10.1099/vir.0.81532-0.
   Google Scholar
• Sakon N, Yamazaki K, Nakata K, Kanbayashi D, Yoda T, Mantani M, Kase T, Takahashi K, Komano J. Impact of genotype-specific herd immunity on the circulatory dynamism of norovirus: a 10-year longitudinal study of viral acute gastroenteritis. J Infect Dis. 2015;211(6):879–888. doi:10.1093/infdis/jiu496.
   Google Scholar
• Saito M, Goel-Apaza S, Espetia S, Velasquez D, Cabrera L, Loli S, Crabtree JE, Black RE, Kosek M, Checkley W, et al. Multiple norovirus infections in a birth cohort in a Peruvian Periurban community. Clin Infect Dis. 2014;58(4):483–491. doi:10.1093/cid/cit763.
   Google Scholar
• Nelson MI, Mahfuz M, Chhabra P, Haque R, Seidman JC, Hossain I, McGrath M, Ahmed AMS, Knobler S, Vinje J, et al. Genetic diversity of noroviruses circulating in a pediatric cohort in Bangladesh. J Infect Dis. 2018;218(12):1937–1942. doi:10.1093/infdis/jiy454.
   Google Scholar
• Simmons K, Gambhir M, Leon J, Lopman B. Duration of immunity to norovirus gastroenteritis. Emerg Infect Dis. 2013;19(8):1260–1267. doi:10.3201/eid1908.130472.
   Google Scholar
• Chhabra P, Rouhani S, Browne H, Yori PP, Salas MS, Olortegui MP, Moulton LH, Kosek MN, Vinje J. Homotypic and heterotypic protection and risk of re-infection following natural norovirus infection in a highly endemic setting. Clin Infect Dis. 2021;72(2):222–229. doi:10.1093/cid/ciaa019.
   Google Scholar
• Lopman BA, Trivedi T, Vicuna Y, Costantini V, Collins N, Gregoricus N, Parashar U, Sandoval C, Broncano N, Vaca M, et al. Norovirus infection and disease in an ecuadorian birth cohort: association of certain norovirus genotypes with host FUT2 secretor status. J Infect Dis. 2015;211(11):1813–1821. doi:10.1093/infdis/jiu672.
   Google Scholar
• Lindesmith LC, Beltramello M, Swanstrom J, Jones TA, Corti D, Lanzavecchia A, Baric RS. Serum immunoglobulin A cross-strain blockade of human noroviruses. Open Forum Infect Dis. 2015;2(3):ofv084. doi:10.1093/ofid/ofv084.
   Google Scholar
• Lindesmith L, Moe C, Lependu J, Frelinger JA, Treanor J, Baric RS. Cellular and humoral immunity following Snow Mountain virus challenge. J Virol. 2005;79(5):2900–2909. doi:10.1128/JVI.79.5.2900-2909.2005.
   Google Scholar
• Lindesmith LC, Ferris MT, Mullan CW, Ferreira J, Debbink K, Swanstrom J, Richardson C, Goodwin RR, Baehner F, Mendelman PM, et al. Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial. PLoS Med. 2015;12(3):e1001807. doi:10.1371/journal.pmed.1001807.
   Google Scholar
• Parra GI, Bok K, Taylor R, Haynes JR, Sosnovtsev SV, Richardson C, Green KY. Immunogenicity and specificity of norovirus Consensus GII.4 virus-like particles in monovalent and bivalent vaccine formulations. Vaccine. 2012;30(24):3580–3586. doi:10.1016/j.vaccine.2012.03.050.
   Google Scholar
• Tohma K, Lepore CJ, Ford-Siltz LA, Parra GI. Evolutionary dynamics of non-GII genotype 4 (GII.4) noroviruses reveal limited and independent diversification of variants. J Gen Virol. 2018;99(8):1027–1035. doi:10.1099/jgv.0.001088.
   Google Scholar
• Lindesmith LC, Donaldson EF, Lobue AD, Cannon JL, Zheng DP, Vinje J, Baric RS. Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med. 2008;5(2):e31. doi:10.1371/journal.pmed.0050031.
   Google Scholar
• Debbink K, Lindesmith LC, Donaldson EF, Costantini V, Beltramello M, Corti D, Swanstrom J, Lanzavecchia A, Vinje J, Baric RS. Emergence of new pandemic GII.4 Sydney norovirus strain correlates with escape from herd immunity. J Infect Dis. 2013;208:1877–1887.
   Google Scholar
• Lindesmith LC, Beltramello M, Donaldson EF, Corti D, Swanstrom J, Debbink K, Lanzavecchia A, Baric RS. Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog. 2012;8:e1002705.
   Google Scholar
• Debbink K, Donaldson EF, Lindesmith LC, Baric RS. Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity. J Virol. 2012;86(2):1214–1226. doi:10.1128/JVI.06189-11.
   Google Scholar
• Parra GI, Abente EJ, Sandoval-Jaime C, Sosnovtsev SV, Bok K, Green KY. Multiple antigenic sites are involved in blocking the interaction of GII.4 norovirus capsid with ABH histo-blood group antigens. J Virol. 2012;86(13):7414–7426. doi:10.1128/JVI.06729-11.
   Google Scholar
• Lindesmith LC, Costantini V, Swanstrom J, Debbink K, Donaldson EF, Vinje J, Baric RS. Emergence of a norovirus GII.4 strain correlates with changes in evolving blockade epitopes. J Virol. 2013;87(5):2803–2813. doi:10.1128/JVI.03106-12.
   Google Scholar
• Tohma K, Lepore CJ, Gao Y, Ford-Siltz LA, Parra GI, Baric RS, Estes MK. Population Genomics of GII.4 Noroviruses Reveal Complex Diversification and New Antigenic Sites Involved in the Emergence of Pandemic Strains. MBio. 2019;10(5). doi:10.1128/mBio.02202-19.
   Google Scholar
• Shanker S, Czako R, Sapparapu G, Alvarado G, Viskovska M, Sankaran B, Atmar RL, Crowe JE Jr., Estes MK, Prasad BV. Structural basis for norovirus neutralization by an HBGA blocking human IgA antibody. Proc Natl Acad Sci U S A. 2016;113(40):E5830–E5837. doi:10.1073/pnas.1609990113.
   Google Scholar
• Angeletti D, Yewdell JW. Understanding and Manipulating Viral Immunity: antibody Immunodominance Enters Center Stage. Trends Immunol. 2018;39(7):549–561. doi:10.1016/j.it.2018.04.008.
   Google Scholar
• Eggink D, Goff PH, Palese P. Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain. J Virol. 2014;88(1):699–704. doi:10.1128/JVI.02608-13.
   Google Scholar
• McGuire AT, Dreyer AM, Carbonetti S, Lippy A, Glenn J, Scheid JF, Mouquet H, Stamatatos L. HIV antibodies. Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies. Science. 2014;346(6215):1380–1383. doi:10.1126/science.1259206.
   Google Scholar
• Garrity RR, Rimmelzwaan G, Minassian A, Tsai WP, Lin G, De Jong JJ, Goudsmit J, Nara PL. Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J Immunol. 1997;159:279–289.
   Google Scholar
• Lok SM, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ, Sukupolvi-Petty S, Sedlak D, Fremont DH, Chipman PR, Roehrig JT, et al. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol. 2008;15(3):312–317. doi:10.1038/nsmb.1382.
   Google Scholar
• Lindesmith LC, Mallory ML, Debbink K, Donaldson EF, Brewer-Jensen PD, Swann EW, Sheahan TP, Graham RL, Beltramello M, Corti D, et al. Conformational occlusion of blockade antibody epitopes, a novel mechanism of gii.4 human norovirus immune evasion. mSphere. 2018;3(1). doi:10.1128/mSphere.00518-17.
   Google Scholar
• Lindesmith LC, Donaldson EF, Beltramello M, Pintus S, Corti D, Swanstrom J, Debbink K, Jones TA, Lanzavecchia A, Baric RS. Particle conformation regulates antibody access to a conserved GII.4 norovirus blockade epitope. J Virol. 2014;88(16):8826–8842. doi:10.1128/JVI.01192-14.
   Google Scholar
• Chan MC, Lee N, Hung TN, Kwok K, Cheung K, Tin EK, Lai RW, Nelson EA, Leung TF, Chan PK. Rapid emergence and predominance of a broadly recognizing and fast-evolving norovirus GII.17 variant in late 2014. Nat Commun. 2015;6(1):10061. doi:10.1038/ncomms10061.
   Google Scholar
• Matsushima Y, Ishikawa M, Shimizu T, Komane A, Kasuo S, Shinohara M, Nagasawa K, Kimura H, Ryo A, Okabe N, et al. Genetic analyses of GII.17 norovirus strains in diarrheal disease outbreaks from December 2014 to March 2015 in Japan reveal a novel polymerase sequence and amino acid substitutions in the capsid region. Euro Surveill. 2015;20(26). doi:10.2807/1560-7917.ES2015.20.26.21173.
   Google Scholar
• Dai YC, Xia M, Huang Q, Tan M, Qin L, Zhuang YL, Long Y, Li JD, Jiang X, Zhang XF. Characterization of antigenic relatedness between GII.4 and GII.17 noroviruses by use of serum samples from norovirus-infected patients. J Clin Microbiol. 2017;55(12):3366–3373. doi:10.1128/JCM.00865-17.
   Google Scholar
• Ao Y, Wang J, Ling H, He Y, Dong X, Wang X, Peng J, Zhang H, Jin M, Duan Z. Norovirus GII.P16/GII.2-associated gastroenteritis, China, 2016. Emerg Infect Dis. 2017;23(7):1172–1175. doi:10.3201/eid2307.170034.
   Google Scholar
• Lu J, Fang L, Sun L, Zeng H, Li Y, Zheng H, Wu S, Yang F, Song T, Lin J, et al. Association of GII.P16-GII.2 recombinant norovirus strain with increased norovirus outbreaks, Guangdong, China, 2016. Emerg Infect Dis. 2017;23(7):1188–1190. doi:10.3201/eid2307.170333.
   Google Scholar
• Niendorf S, Jacobsen S, Faber M, Eis-Hubinger AM, Hofmann J, Zimmermann O, Hohne M, Bock CT. Steep rise in norovirus cases and emergence of a new recombinant strain GII.P16-GII.2, Germany, winter 2016. Euro Surveill. 2017;22(4). doi:10.2807/1560-7917.ES.2017.22.4.30447.
   Google Scholar
• Lindesmith LC, Kocher JF, Donaldson EF, Debbink K, Mallory ML, Swann EW, Brewer-Jensen PD, Baric RS. Emergence of novel human norovirus GII.17 strains correlates with changes in blockade antibody epitopes. J Infect Dis. 2017;216(10):1227–1234. doi:10.1093/infdis/jix385.
   Google Scholar
• Swanstrom J, Lindesmith LC, Donaldson EF, Yount B, Baric RS. Characterization of blockade antibody responses in GII.2.1976 Snow Mountain virus-infected subjects. J Virol. 2014;88(2):829–837. doi:10.1128/JVI.02793-13.
   Google Scholar
• Atmar RL, Cramer JP, Baehner F, Han C, Borkowski A, Mendelman PM. An exploratory study of the salivary immunoglobulin a responses to 1 dose of a norovirus virus-like particle candidate vaccine in healthy adults. J Infect Dis. 2019;219(3):410–414. doi:10.1093/infdis/jiy529.
   Google Scholar
• Vaxart’s Tableted Oral Bivalent Norovirus Vaccine Meets Primary and Secondary Endpoints in Phase1b Study. 2019 September 25, [ cited 2020 August 12]; https://investors.vaxart.com/news-releases/news-release-details/vaxarts-tableted-oral-bivalent-norovirus-vaccine-meets-primary.
   Google Scholar
• Kim L, Liebowitz D, Lin K, Kasparek K, Pasetti MF, Garg SJ, Gottlieb K, Trager G, Tucker SN. Safety and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo-controlled trial. JCI Insight. 2018;3(13). doi:10.1172/jci.insight.121077.
   Google Scholar
• Blazevic V, Malm M, Arinobu D, Lappalainen S, Vesikari T. Rotavirus capsid VP6 protein acts as an adjuvant in vivo for norovirus virus-like particles in a combination vaccine. Hum Vaccin Immunother. 2016;12(3):740–748. doi:10.1080/21645515.2015.1099772.
   Google Scholar
• Tamminen K, Lappalainen S, Huhti L, Vesikari T, Blazevic V, Zhou P. Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice. PLoS One. 2013;8(7):e70409. doi:10.1371/journal.pone.0070409.
   Google Scholar
• Blazevic V, Lappalainen S, Nurminen K, Huhti L, Vesikari T. Norovirus VLPs and rotavirus VP6 protein as combined vaccine for childhood gastroenteritis. Vaccine. 2011;29(45):8126–8133. doi:10.1016/j.vaccine.2011.08.026.
   Google Scholar
• Santi L, Batchelor L, Huang Z, Hjelm B, Kilbourne J, Arntzen CJ, Chen Q, Mason HS. An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles. Vaccine. 2008;26(15):1846–1854. doi:10.1016/j.vaccine.2008.01.053.
   Google Scholar
• Guo L, Wang J, Zhou H, Si H, Wang M, Song J, Han B, Shu Y, Ren L, Qu J, et al. Intranasal administration of a recombinant adenovirus expressing the norovirus capsid protein stimulates specific humoral, mucosal, and cellular immune responses in mice. Vaccine. 2008;26(4):460–468. doi:10.1016/j.vaccine.2007.11.039.
   Google Scholar
• Ma Y, Li J. Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: a new vaccine candidate against an important noncultivable virus. J Virol. 2011;85(6):2942–2952. doi:10.1128/JVI.02332-10.
   Google Scholar
• Tan M, Fang P, Chachiyo T, Xia M, Huang P, Fang Z, Jiang W, Jiang X. Noroviral P particle: structure, function and applications in virus-host interaction. Virology. 2008;382(1):115–123. doi:10.1016/j.virol.2008.08.047.
   Google Scholar
• Su W, Gao J, Zang Y, Wu H, Wang L, Hu H, Yu X, Kong W, Jiang C. Production, characterization and immunogenicity of P particles derived from norovirus GII.4 genotype 2004 variant. Acta Virol. 2015;59(1):33–39. doi:10.4149/av_2015_01_33.
   Google Scholar
• Shiota T, Okame M, Takanashi S, Khamrin P, Takagi M, Satou K, Masuoka Y, Yagyu F, Shimizu Y, Kohno H, et al. Characterization of a broadly reactive monoclonal antibody against norovirus genogroups I and II: recognition of a novel conformational epitope. J Virol. 2007;81(22):12298–12306. doi:10.1128/JVI.00891-07.
   Google Scholar
• Okuya K, Yoshida R, Manzoor R, Saito S, Suzuki T, Sasaki M, Saito T, Kida Y, Mori-Kajihara A, Kondoh T, et al. A potential role of non-neutralizing IgA antibodies in cross-protective immunity against influenza A viruses of multiple hemagglutinin subtypes. J Virol. 2020;94(12). doi:10.1128/JVI.00408-20.
   Google Scholar
• Asthagiri Arunkumar G, Ioannou A, Wohlbold TJ, Meade P, Aslam S, Amanat F, Ayllon J, Garcia-Sastre A, Krammer F, Schultz-Cherry S. Broadly Cross-Reactive, Nonneutralizing Antibodies against Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection against Lethal Viral Challenge in Mice. J Virol. 2019;93(6). doi:10.1128/JVI.01696-18.
   Google Scholar
• Shibuya M, Aoshi T, Kuroda E, Yoshioka Y, Schultz-Cherry S. Murine cross-reactive non-neutralizing polyclonal IgG1 antibodies induced by influenza vaccine inhibit the cross-protective effect of IgG2 against heterologous virus in mice. J Virol. 2020;94(12). doi:10.1128/JVI.00323-20.
   Google Scholar
• Lu LL, Suscovich TJ, Fortune SM, Alter G. Beyond binding: antibody effector functions in infectious diseases. Nat Rev Immunol. 2018;18(1):46–61. doi:10.1038/nri.2017.106.
   Google Scholar
• Bhide Y, Dong W, Gribonika I, Voshart D, Meijerhof T, De Vries-idema J, Norley S, Guilfoyle K, Skeldon S, Engelhardt OG, et al. Cross-protective potential and protection-relevant immune mechanisms of whole inactivated influenza virus vaccines are determined by adjuvants and route of immunization. Front Immunol. 2019;10:646. doi:10.3389/fimmu.2019.00646.
   Google Scholar
• Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, Fourneau MA, Colau B, Suzich J, Losonksy G, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 2006;24(33–34):5937–5949. doi:10.1016/j.vaccine.2006.06.005.
   Google Scholar